-
Gitoformate
- names:
Gitoformate
- CAS号:
10176-39-3
MDL Number: - MF(分子式): C46H64O19 MW(分子量): 921
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | (2R,3R,4S,6S)-6-(((2R,3R,4S,6S)-4-(formyloxy)-6-(((2R,3R,4S,6R)-4-(formyloxy)-6-(((3S,5R,8R,9S,10S,13R,14S,16S,17R)-16-(formyloxy)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3,4-diyl diformate |
| 英文别名 | Gitoformate; Formiloxin; Pentaformylgitoxin; AC 2770 |
| CAS号 | 10176-39-3 |
| Inchi | InChI=1S/C46H64O19/c1-24-41(59-23-51)32(55-19-47)14-38(60-24)64-43-26(3)62-39(16-34(43)57-21-49)65-42-25(2)61-37(15-33(42)56-20-48)63-29-8-10-44(4)28(13-29)6-7-31-30(44)9-11-45(5)40(27-12-36(52)54-18-27)35(58-22-50)17-46(31,45)53/h12,19-26,28-35,37-43,53H,6-11,13-18H2,1-5H3/t24-,25-,26-,28-,29+,30+,31-,32+,33+,34+,35+,37+,38+,39+,40+,41-,42-,43-,44+,45-,46+/m1/s1 |
| InchiKey | DOMHWKQEPDYUQX-LJAQBGIBSA-N |
| 分子式 Formula | C46H64O19 |
| 分子量 Molecular Weight | 921 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | Gitoformate(CAS:10176-39-3):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | Gitoformate is used to treat cardiac and renal insufficiency, |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Kubin S, Woodcock BG, Menke G, Rietbrock N. [Postprandial delay of drug absorption in a gitoformate model]. Arzneimittelforschung. 1987 Dec;37(12):1376-8. German. PubMed PMID: 3449065. |
| [2]Reuter N, Meyer F. [Effects of pentaformylgitoxin (gitoformate) on the cardiovascular system of anesthetized cats]. Arzneimittelforschung. 1976;26(6):1201-5. German. PubMed PMID: 989416. |
| [3] Dei Cas L, Manca C, Assanelli D, Vasini G, Pelagatti T, Buia E. [Pharmacokinetics and pharmacodynamics of gitoformate in subjects with atrial fibrillation]. Boll Soc Ital Cardiol. 1981;26(12):2383-4. Italian. PubMed PMID: 7185409. |
| [4] Dei Cas L, Vasini G, Manca C, Buia E, Pelagatti T, Bernardini B. [Pharmacokinetics of gitoformate in subjects with renal insufficiency under dialysis treatment]. Boll Soc Ital Cardiol. 1981;26(12):2381-2. Italian. PubMed PMID: 7185408. |
| [5] Lesne M, Cremers S, Carlier J. [Pharmacokinetic and biopharmaceutic parameters of gitoformate]. Therapie. 1978 Nov-Dec;33(6):723-34. French. PubMed PMID: 746519. |
6: Rietbrock N, Woodcock BG, Hrazdil U. [Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency]. Arzneimittelforschung. 1984;34(8):915-7. German. PubMed PMID: 6541927.7: Dei Cas L, Vasini G, Bianchi G, Manca C, Ghinelli R, Mansour M. [Gitoformate in chronic renal insufficiency: pharmacokinetic aspects]. Boll Soc Ital Cardiol. 1979;24(2):209-12. Italian. PubMed PMID: 548097.8: Dei Cas L, Biasucci LM, Buia E, Frustaci A, Manca C, Metra M, Rebuzzi AG. [Circadian aspects of the heart rate in atrial fibrillation patients: the comparative effect of digoxin and pentaformylgitoxin]. Cardiologia. 1983 Dec;28(12):1019-25. Italian. PubMed PMID: 6681261.9: Kesteloot H, Brasseur L, Carlier J, Demanet JC, Andriange M, Bataille G, Collignon P, Cosyns J, Vancrombreucq JC, Van Durme JP, Willems J, Foucart G. Effect of digitalis on the left ventricular ejection time: a multicenter double-blind comparative study of digitoxin and pentaformylgitoxin in normal subjects. Acta Cardiol. 1969;24(4):409-25. PubMed PMID: 4928444.10: Dei Cas L, Biasucci LM, Buia E, Frustaci A, Manca C, Metra M, Rebuzzi AG. [Circadian aspects of heart rate in patients with atrial fibrillation: comparative influence of digoxin and pentaformylgitoxin]. Cardiologia. 1983 Dec;28(12):1019-25. Italian. PubMed PMID: 6687204.1
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


